Rolle von Biomarkern zur Risikostratifizierung in der Prävention kardiovaskulärer Erkrankungen

Schlüsselwörter

Biomarker - Prognose - natriuretische Peptide - BNP - Nt-proBNP - C-reaktives Protein

Keywords

biomarker - prognosis - natriuretic peptides - BNP - Nt-proBNP - C-reactive protein

Literatur

• 1 Blankenberg S, McQueen M J, Smieja M. et al . Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.  Circulation. 2006;  114 201-208
• 2 Danesh J, Wheeler J G, Hirschfield G M. et al . C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.  N Engl J Med. 2004;  350 1387-1397
• 3 Dickstein K, Cohen-Solal A, Filippatos G. et al . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).  Eur Heart J. 2008;  29 2388-2442
• 4 Kistorp C, Raymond I, Pedersen F. et al . N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.  JAMA. 2005;  293 1609-1616
• 5 Maisel A S, Krishnaswamy P, Nowak R M. et al . Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.  N Engl J Med. 2002;  347 161-167
• 6 Marcovina S M, Crea F, Davignon J. et al . Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools.  J Intern Med. 2007;  261 214-234
• 7 McKie P M, Rodeheffer R J, Cataliotti A. et al . Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure.  Hypertension. 2006;  47 874-880
• 8 Pai J K, Pischon T, Ma J. et al . Inflammatory markers and the risk of coronary heart disease in men and women.  N Engl J Med. 2004;  351 2599-2610
• 9 Pencina M J, D’Agostino Sr R B, Larson M G, Massaro J M, Vasan R S. Predicting the 30-year risk of cardiovascular disease: the framingham heart study.  Circulation. 2009;  119 3078-3084
• 10 Ridker P M, Rifai N, Rose L, Buring J E, Cook N R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.  N Engl J Med. 2002;  347 1557-1565
• 11 Sinning J M, Bickel C, Messow C M. et al . Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study.  Eur Heart J. 2006;  27 2962-2968
• 12 van der Meer I M, de Maat M P, Kiliaan A J. et al . The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study.  Arch Intern Med. 2003;  163 1323-1328
• 13 Vasan R S. Biomarkers of cardiovascular disease: molecular basis and practical considerations.  Circulation. 2006;  113 2335-2362
• 14 Wang T J, Larson M G, Levy D. et al . Plasma natriuretic peptide levels and the risk of cardiovascular events and death.  N Engl J Med. 2004;  350 655-663
• 15 Wang T J, Gona P, Larson M G. et al . Multiple biomarkers for the prediction of first major cardiovascular events and death.  N Engl J Med. 2006;  355 2631-2639
• 16 Wilson P W, Nam B H, Pencina M. et al . C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study.  Arch Intern Med. 2005;  165 2473-2478
• 17 Zethelius B, Berglund L, Sundstrom J. et al . Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.  N Engl J Med. 2008;  358 2107-2116